Product Details
Erlotinib for Tablets BP
Product Name
:
Erlotinib for Tablets BP
Brand Name
:
VERERLO
Available Strength
:
150 mg
Packing
:
30 Tablets
Pack Insert/Leaflet
:
According To Your Needs
These film-coated tablets meet British Pharmacopoeia standards, supporting targeted treatment for EGFR-mutated non-small cell lung cancer. Oncologists prescribe Erlotinib for patients whose tumors test positive for specific EGFR mutations.
Erlotinib BP (150 mg) is a tyrosine kinase inhibitor that blocks EGFR signaling, interrupting the growth pathway driving EGFR-mutated tumors. As a result, it helps control tumor progression in eligible patients. Because of this targeted mechanism, oncology specialists prescribe it under close supervision as part of an individualized treatment plan. Therefore, hospitals and oncology clinics restrict its use to patients under specialist care.
Key Features
- Meets BP (British Pharmacopoeia) standards for consistent quality
- Delivers targeted EGFR inhibition for lung cancer therapy
- Ensures accurate, validated dosing in every batch
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncologist supervision
- Restricted to hospital, oncology clinic, and specialist institutional supply